Stock SAZ STADA ARZNEIMITTEL
Add to a list
To use this feature you must be a member
Log inSign up

All News STADA Arzneimittel

Equities

SAZ

DE0007251803

Delayed Xetra
Other stock markets
 		5-day change 1st Jan Change
- EUR -.--% Intraday chart for STADA Arzneimittel -1.95% -8.87%
2023 Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar MT
2021 Sanofi Divests 16 Brands From European Consumer Healthcare Portfolio DJ

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy
AQ
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
AQ
Xbrane and STADA partner with Valorum Biologics to commercialize ranibizumab biosimilar candidate in the US
AQ
Xbrane has received additional subscription undertakings corresponding to approximately SEK 18.1 million in the Company's rights issue
AQ
Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar
MT
Calliditas announces filing with UK MHRA for Kinpeygo in IgA nephropathy
AQ
STADA and Calliditas announce the filing for full marketing authorization of Kinpeygo® in the EU
AQ
Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet
AQ
STADA and Xbrane weigh options for ranibizumab biosimilar candidate
AQ
Xbrane announce U.S. FDA filing acceptance for a Lucentis® (ranibizumab) biosimilar candidate
AQ
STADA AND XBRANE LAUNCH XIMLUCI AS RANIBIZUMAB BIOSIMILAR IN GERMANY
AQ
STADA and Xbrane launch Ximluci® as ranibizumab biosimilar in Germany
AQ
STADA AND XBRANE SUPPLY XIMLUCI IN ENGLAND UNDER NHS CONTRACT
AQ
STADA and Xbrane supply Ximluci® (ranibizumab) in England under NHS contract
AQ
STADA and Xbrane launch ranibizumab to support patient access in Europe
AQ
AFR: STADA Arzneimittel AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQ
AFR: STADA Arzneimittel AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQ
European Biosimilar Regulatory Updates
AQ
Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy
AQ
STADA and Xbrane obtain British approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SAZ Stock
  4. News STADA Arzneimittel